Predictors of the development of hepatorenal syndrome
https://doi.org/10.51523/2708-6011.2021-18-4-9
Abstract
Objective. To identify the predictors of the development of hepatorenal syndrome in patients with liver cirrhosis.
Materials and methods. We analyzed the medical records of 79 patients diagnosed with liver cirrhosis. The laboratory research included general and biochemical blood tests. The general blood test measured erythrocyte and leukocyte counts. The biochemical blood test measured the content of ALT (U/L), AST (E/L), total bilirubin (μmol/L), direct bilirubin (μmol/L), indirect bilirubin (μmol/L), alkaline phosphatase (U/L), albumin (g/L), urea (mmol/L), creatinine (mmol/L), cholesterol (mmol/L).Viral hepatitis markers were determined for all the patients.
Results. The predictors of the development of hepatorenal syndrome were identified: increased leukocyte count, increased total and indirect bilirubin levels, urea level and decreased erythrocyte count and albumin level. The most specific predictors were the amount of indirect bilirubin (98 %) and the content of albumin in the serum (89.8 %), and the most sensitive predictors were AST (96.7 %) and the content of red blood cells and creatinine (73.3 %).
Conclusion. The most significant predictors of the development obtained will contribute to the diagnosis of the development of hepatorenal syndrome in patients with liver cirrhosis.
About the Authors
E. A. Kozich
Gomel State Medical University
Belarus
Belarus
Elena A. Kozich, Master, Assistant Lecturer at the Department of Infectious Diseases
Gomel
E. L. Krasavtsev
Gomel State Medical University
Belarus
Belarus
Evgene L. Krasavtsev, DMedSc, Head of the Department of Infectious Diseases
Gomel
References
1. Lata J. Hepatorenal syndrome. World J Gastroen- terol. 2012 Sep 28;18(36):4978-4984. DOI: https://doi.org/10.3748/wjg.v18.i36.4978
2. Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the Internation- al Club of Ascites (ICA) consensus document. J Hepatol. 2019 Oct;71(4):811-822. DOI: https://doi.org/10.1016/j.jhep.2019.07.002
3. Facciorusso A. Hepatorenal Syndrome Type 1: Current Challenges And Future Prospects. Ther Clin Risk Manag. 2019 Nov 27;15:1383-1391. DOI: https://doi.org/10.2147/TCRM.S205328
4. Francesco S, Gerbes A, Ginès P, Wong F, et al. Diagnosis, prevention and treatment of hepatorenal syn- drome in cirrhosis. Gut. 2007 Sep;56(9):1310-1318. DOI: https://doi.org/10.1136/gut.2006.107789
5. Acevedo JG, Cramp ME. Hepatorenal syndrome: Update on diagnosis and therapy. World J Hepatol. 2017 Feb 28;9(6):293-299. DOI: https://doi.org/10.4254/wjh.v9.i6.293
6. Low G, Alexander GJM, Lomas DJ. Hepatorenal Syndrome: Aetiology, Diagnosis, and Treatment. Gastroen- terol Res Pract.2015;2015:207012. DOI: https://doi.org/10.1155/2015/207012
7. Ginès A, Escorsell A, Ginès P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syn- drome in cirrhosis with ascites. Gastroenterology. 1993 Jul; 105(1):229-236. DOI: https://doi.org/10.1016/0016-5085(93)90031-7
8. Gines P, Guevara M. Hepatorenal syndrome. Lancet. 2003 Nov 29;362(9398):1819-1827. DOI: https://doi.org/10.1016/S0140-6736(03)14903-3
9. Acevedo JG, Cramp ME. Hepatorenal syndrome: Update on diagnosis and therapy. World J Hepatol. 2017 Feb 28;9(6):293-299. DOI: https://doi.org/10.4254/wjh.v9.i6.293
10. Mindikoglu AL, Weir MR. Current concepts in the diagnosis and classification of renal dysfunction in cirrho- sis. Am J Nephrol. 2013;38(4):345-354. DOI: https://doi.org/10.1159/000355540
Review
For citations:
Kozich E.A., Krasavtsev E.L. Predictors of the development of hepatorenal syndrome. Health and Ecology Issues. 2021;18(4):69-73. (In Russ.) https://doi.org/10.51523/2708-6011.2021-18-4-9
Views: 360
Email this article 